Kymera Therapeutics, Inc. Common Stock (KYMR) is a publicly traded Healthcare sector company. As of October 22, 2026, KYMR trades at $110.98 with a market cap of $9.37B and a P/E ratio of -33.04. KYMR moved -1.55% today. Year to date, KYMR is +53.09%; over the trailing twelve months it is +98.66%. Its 52-week range spans $19.45 to $130.05. Analyst consensus is strong buy with an average price target of $141.50. Rallies surfaces KYMR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies AI research for KYMR combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
| Metric | Value |
|---|---|
| Price | $110.98 |
| Market Cap | $9.37B |
| P/E Ratio | -33.04 |
| EPS | $-3.25 |
| Dividend Yield | 0.00% |
| 52-Week High | $130.05 |
| 52-Week Low | $19.45 |
| Volume | 739.21K |
| Avg Volume | 0 |
| Revenue (TTM) | $105.00M |
| Net Income | $-299.60M |
| Gross Margin | 0.00% |
16 analysts cover KYMR: 0 strong buy, 14 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $141.50.